Results 21 to 30 of about 131 (88)
97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View [PDF]
Open Forum Infectious Diseases, 2021 Abstract Background Dengue fever is a mosquito-borne viral disease endemic in 128 countries. An unmet clinical need remains for an effective vaccine that can be used more broadly than the vaccine presently available.
Tricou, Vianney +8 more
openaire +1 more source
Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
The American Journal of Tropical Medicine and Hygiene, 2023 ABSTRACT. In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue between the first dose and the end of the study, ∼57 months later (patients received the second dose 3 months after the first dose).
Xavier Sáez‐Llorens +9 more
openaire +2 more sources
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
Revista Panamericana de Salud Pública, 2021 Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. Participants aged 12–17 years were randomized 3:
Shibadas Biswal +10 more
doaj +1 more source
PLoS Neglected Tropical Diseases, 2023 BackgroundYellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individuals ...
Vianney Tricou +9 more
doaj +1 more source
International Journal of Infectious Diseases, 2023 Intro: An ongoing, long-term, phase 3 trial (NCT02747927) in eight dengueendemic countries across Asia and Latin America is evaluating the efficacy, safety, and immunogenicity of Takeda's tetravalent dengue vaccine candidate, TAK-003.
A. Green +4 more
doaj +1 more source
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination [PDF]
The Journal of Infectious Diseases, 2020 Abstract Background Takeda’s dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 ...
López-Medina, Eduardo +29 more
openaire +2 more sources
Human Vaccines & Immunotherapeutics, 2023 Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year.
Sanjay S. Patel +5 more
doaj +1 more source
DISEASE IMPACT AND COST-EFFECTIVENESS OF A NEW DENGUE VACCINE TAK003 IN THAILAND
International Journal of Infectious Diseases, 2023 Intro: Dengue, a vector-borne disease, is a global threat to public health with incidence increased from 0.5 to 5.2 million cases between 2010 and 2019.
J. Shen +8 more
doaj +1 more source
Clinical Infectious Diseases, 2022 Abstract Background An unmet medical need remains for an effective dengue tetravalent vaccine that can be administered irrespective of previous dengue exposure. TAK-003, a dengue tetravalent vaccine, has demonstrated efficacy in an ongoing phase 3 trial in children and adolescents living in dengue ...
Patel, Sanjay S +3 more
openaire +2 more sources
Human Vaccines & Immunotherapeutics, 2020 Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials.
Mark Turner +13 more
doaj +1 more source